Obesity and oxidative stress intensify psoriasis through activating IL-17/IL-23 pathway

被引:0
作者
Vikasari, Suci Nar [1 ,3 ]
Sukandar, Elin Yulinah [3 ]
Suciati, Tri [2 ]
Adnyana, I. Ketut [2 ]
机构
[1] Inst Teknol Bandung, Sch Pharm, Doctoral Program Pharm, Bandung, Indonesia
[2] Inst Teknol Bandung, Sch Pharm, Bandung, Indonesia
[3] Univ Jenderal Achmad Yani, Fac Pharm, Cimahi, Indonesia
来源
PHYSIOLOGY AND PHARMACOLOGY | 2024年 / 28卷 / 01期
关键词
Psoriasis; Autoimmune; Obese; Oxidative stress; IL-17/IL-23; pathway; PATHOPHYSIOLOGY; PATHOGENESIS; UPDATE;
D O I
10.61186/phypha.28.1.18
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Psoriasis is an autoimmune disease characterized by keratinocyte hyperproliferation and skin thickening. Psoriasis is caused by a complicated interaction between the innate and acquired immune systems. In the skin, this reaction produces abnormal T helper cell (Th1, Th17, and Th23) reactivation. Keratinocyte hyperproliferation is caused by increased cell (TNF-alpha), and interferon-gamma (INF-gamma). Obesity, free fatty acids, microorganisms in the skin and digestive tract, free radicals in the body, and the cardiovascular system are also essential variables in psoriasis. Several variables influence the cytokine activation of the IL17/IL-23 pathway. Obesity, which is marked by changes in lipid profile in psoriasis patients, is linked to increased oxidative stress and the generation of proinflammatory cytokines, both of which can potentially trigger psoriasis relapse. Antioxidant-rich diet and intake can be employed as one of the stages in preventing psoriasis recurrence.
引用
收藏
页码:18 / 26
页数:9
相关论文
共 50 条
  • [31] The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review
    Tsiogka, Aikaterini
    Gregoriou, Stamatios
    Stratigos, Alexander
    Soulaidopoulos, Stergios
    Rompoti, Natalia
    Panagakis, Pantelis
    Papoutsaki, Marina
    Kostakis, Panagiotis
    Kontochristopoulos, George
    Tsioufis, Konstantinos
    Campanati, Anna
    Offidani, Annamaria
    Vlachopoulos, Charalambos
    Rigopoulos, Dimitrios
    [J]. BIOMEDICINES, 2023, 11 (02)
  • [32] Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study
    Dapavo, Paolo
    Siliquini, Niccolo
    Mastorino, Luca
    Avallone, Gianluca
    Merli, Martina
    Agostini, Andrea
    Cariti, Caterina
    Viola, Riccardo
    Stroppiana, Elena
    Verrone, Anna
    Ortoncelli, Michela
    Quaglino, Pietro
    Ribero, Simone
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2352 - 2357
  • [33] Anti IL-17 in psoriasis
    Ly, Karen
    Smith, Mary P.
    Thibodeaux, Quinn
    Reddy, Vidhatha
    Liao, Wilson
    Bhutani, Tina
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (11) : 1185 - 1194
  • [34] The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis
    AbuHilal, Mohn'd
    Walsh, Scott
    Shear, Neil
    [J]. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2016, 20 (06) : 509 - 516
  • [35] IL-23/IL-17 axis levels in gingival crevicular fluid of subjects with periodontal disease: a systematic review
    Alarcon-Sanchez, Mario Alberto
    Guerrero-Velazquez, Celia
    Becerra-Ruiz, Julieta Sarai
    Rodriguez-Montano, Ruth
    Avetisyan, Anna
    Heboyan, Artak
    [J]. BMC ORAL HEALTH, 2024, 24 (01)
  • [36] Effects of Cyclosporine on Palmoplantar Pustulosis and Serum Expression of IL-17, IL-23, and TNF-α
    Jin, Xian-Hua
    Chen, Xi
    Mou, Yan
    Xia, Jian-Xin
    [J]. DERMATOLOGY AND THERAPY, 2019, 9 (03) : 547 - 552
  • [37] NET Formation in Bullous Pemphigoid Patients With Relapse Is Modulated by IL-17 and IL-23 Interplay
    Giusti, Delphine
    Bini, Estela
    Terryn, Christine
    Didier, Kevin
    Le Jan, Sebastien
    Gatouillat, Gregory
    Durlach, Anne
    Nesmond, Stephane
    Muller, Celine
    Bernard, Philippe
    Antonicelli, Frank
    Bach Nga Pham
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [38] Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris
    Potestio, Luca
    D'Agostino, Michela
    Portarapillo, Antonio
    Esposito, Valeria
    Tommasino, Nello
    Salsano, Antonia
    Guerriero, Luigi
    Martora, Fabrizio
    Megna, Matteo
    [J]. LIFE-BASEL, 2024, 14 (08):
  • [39] The relationship between TNF-α, IL-1, IL-12, IL-17, IL-23, IL-36 expression and treatment response in psoriasis histopathologically and immunohistochemically
    Temiz, Selami Aykut
    Dursun, Recep
    Findik, Siddika
    Ataseven, Arzu
    Isik, Begum
    Ozer, Ilkay
    [J]. CUTANEOUS AND OCULAR TOXICOLOGY, 2024, 43 (03) : 182 - 189
  • [40] Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies
    Bianchi, Elisabetta
    Vecellio, Matteo
    Rogge, Lars
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12